n-Lorem Foundation Applauds FDA’s Important and Highly Constructive Guidance for Individualized ASO Treatments for Patients with Ultra-Rare Conditions
New FDA guidance [...]
n-Lorem Foundation, ChemGenes Announce Collaboration to Support Manufacturing of Individualized Treatments for Patients with Ultra-Rare Diseases
Foundation’s partnership with [...]
n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases
Foundation’s collaboration with [...]
How you can help provide experimental ASO treatments to patients with ultra-ultra-rare diseases.
Over the last three years, [...]
n-Lorem Foundation receives $500,000 donation for providing experimental antisense medicines to treat patients with ultra-rare diseases
CARLSBAD, Calif., April 14, [...]
